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STUDY PROTOCOL 
ABSTRACT
Introduction: New medical devices must have adequate research, such that 
outcomes are known, enabling patients to be consented with knowledge of the safety 
and efficacy of the device to be implanted. Device trials are challenging due to the 
learning curve and iterative assessment of best practice. This study is designed to pilot 
a national collaborative approach to medical device introduction by breast surgeons 
in the UK, using breast localisation devices as an exemplar. The aim is to develop an 
effective and transferable surgical device platform protocol design, with embedded 
shared learning. 
Methods and analysis: The iBRA-net localisation study is a UK based prospective, multi-
centre platform study, comparing the safety and efficacy of novel localisation devices 
with wire-guided breast lesion localisation for wide local excision, using Magseed® as 
the pilot intervention group. Centres performing breast lesion localisation for wide local 
excision or excision biopsy will be eligible to participate if using one of the included devices. 
Further intervention arms will be added as new devices are CE marked. Outcomes will be 
collected via an online database. The primary outcome measure will be identification of 
the index lesion. Participating surgeons will be asked to record shared learning events via 
online questionnaires and focus group interviews to inform future study arms. 
Ethics and dissemination: The study will aim to collect data on 950 procedures for 
each intervention (Magseed® and wire localisation) from UK breast centres over 
an 18-month period. Shared learning will be prospectively evaluated via thematic 
analysis to refine breast localisation technique and to promote early identification of 
potential pitfalls and problems. Results will be presented at national and international 
conferences and published in peer reviewed journals.
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INTRODUCTION
Difficulties exist in trials of surgical innovations where the 
surgeon is learning a new technique and the extent of the 
risks are unknown [1, 2]. The European approval process 
for a new medical device requires the manufacturer 
to demonstrate safety of the device [3], but unlike the 
introduction of a new medicine, there was no requirement 
for clinical studies to provide ongoing efficacy data once 
CE marking is given. Device introduction across the United 
Kingdom (UK) is often driven by the marketing of the 
product by the manufacturer or the distributor [4]. Trials 
of the device are usually performed in small numbers in 
disparate audits or research studies, with variability in 
outcome measures and quality [5, 6]. 
Platform studies offer a potential solution in the 
evaluation of new surgical devices, where multiple 
interventions are evaluated against a common control 
group within a single protocol [7, 8]. The platform design 
facilitates flexibility for a new experimental arm to be 
added and for the control arm to be updated during 
the trial [9], as surgical innovations are developed or 
iteratively refined. Consequently, multiple interventions 
can be evaluated in a perpetual manner under a single 
master protocol [10], which share the same infrastructure 
with standardised trial procedures. Platform studies are 
pertinent in the assessment of new surgical devices, 
where surgical technique or study outcomes may require 
iterative adjustment.
Breast cancer localisation is an area which has seen 
rapid development of new surgical devices [11–13]. Breast 
surgery requires the use of multiple medical devices 
such as meshes, and devices to localise breast lesions 
for excision. Magseed® [14], Hologic Localiser™ [15] 
and Savi Scout® [16] are new devices which may offer 
clinical and logistic benefit over wire-guided breast lesion 
localisation, but conventional clinical trials evaluating 
their efficacy are likely to be limited by learning curves 
and a potential for surgical bias. A multi-arm platform 
study offers an advantage in allowing new experimental 
arms to be added, as these new localisation devices or 
techniques are CE approved.
The IDEAL (idea, development, exploration, 
assessment, long term study) study framework [17] 
sets out the stages through which surgical innovations 
should pass in the assessment of device safety and 
clinical efficacy. Event reporting of unexpected issues 
or outcomes associated with a new surgical device or 
procedure is encouraged [18]. Guidance on how best to 
capture the evidence on shared learning to guide future 
surgical practice is limited [19], however, including an 
assessment of the impact of shared learning during 
the assessment of new devices on learning curves and 
clinical outcomes. 
The iBRA-net group [20] is a collaborative group of UK 
breast surgeons, structured as a part of the Association 
of Breast Surgery, the national body representing breast 
surgeons. The Association of Breast Surgery and iBRA-
net are committed to the evaluation of new devices and 
techniques in breast surgery. iBRA-net was developed 
[20] such that a new device could be evaluated by a 
large group of centres using a common set of outcome 
measures. The aim is to establish a pathway for new 
device introduction to collect outcome data on the 
product, enable shared learning and provide patient 
information resources to allow true informed consent. 
AIMS AND OBJECTIVES
The study protocol is designed to pilot a national 
collaborative approach to medical device introduction 
by breast surgeons in the UK, using breast localisation 
devices as an exemplar. The overall aim is to develop 
an effective and transferable surgical device platform 
protocol design, with embedded shared learning to 
potentially accelerate the learning curve.
The aim of the iBRA-net localisation study is to audit 
and describe the breast lesion localisation rates across 
multiple centres in the United Kingdom. In addition, the 
Highlights 
•	 This protocol outlines a novel methodology for a collaborative national platform study to collate safety and 
efficacy data on new medical devices. Improved registration and audit of new medical devices is a major 
theme of the Cumberlege report of the Independent Medicines and Medical Devices Safety Review. 
•	 We outline a protocol for a UK based multi-centre prospective audit to investigate the safety and efficacy 
of new surgical devices for breast lesion localisation. The study will run as a platform study using wire 
localisation as a control group and Magseed® as the first intervention arm.
•	 The protocol is designed for additional bolt-on intervention arms for other localisation devices, such as 
Hologic Localizer™ and Savi Scout®, when they become available to the European market. This will enable 
comparison of these devices to datasets already collected on wire and Magseed® localisation.
•	 The study includes a novel shared learning methodology using iterative online database reporting and 
surgical interviews to centrally distribute information on learning events, critical governance issues and 
recommended protocols for future use.
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impact of shared learning on the learning curve and 
analysis of secondary outcomes will be determined. 
The primary outcome is to compare the identification 
rates of the index lesion in the excised tissue, between 
women undergoing surgical excision of an impalpable 
breast lesion with wire guided excision as the control 
group, and Magseed® localisation, as the primary 
intervention group. Additional devices will be bolted on as 
a comparator arm in the platform study when approved 
for use in the UK and European market.
Key secondary outcomes include:
1. Clinical outcomes related to the localisation device: 
margin status, accuracy of placement, pathological 
weight of the specimen, duration of surgery, 
perioperative complications or adverse events, 
reoperation rate and cancellations.
2. Shared learning events from qualitative feedback: 
refinement of clinical outcomes or endpoints, patient 
selection criteria and surgical approaches during the 
learning curve.
3. Novel trial design efficacy: qualitative survey 
assessment of whether shared learning 
dissemination within the study changed clinical 
practice or accelerated the learning curve for 
innovative surgical localisation techniques.
4. Collecting national data to inform current practice of 
breast localisation techniques in the UK. 
METHODS
STUDY DESIGN
The iBRA-net localisation study is a UK based prospective, 
multi-centre platform study, with embedded novel 
shared learning methodology, which will compare the 
safety and feasibility of breast localisation devices as an 
exemplar. The study will begin with a National Practice 
questionnaire, designed with quantitative outcomes to 
ascertain which devices are used in the UK and qualitative 
questions to explore what clinicians think about their 
current localisation technique and what change or 
improvements they require. The main study will run as a 
platform cohort study using wire localisation as a control 
group and Magseed® as the first intervention arm, which 
already has CE approval. The study protocol is designed 
to permit additional bolt-on intervention arms as new 
localisation devices are approved for use in the UK and 
European healthcare market. This will enable comparison 
of new devices to data sets already collected on wire and 
Magseed® lesion localisation. 
SETTING
All surgical centres in the United Kingdom performing 
breast lesion localisation for surgical excision will be 
invited to participate. Invitations will be advertised 
through the professional associations, including the 
Association of Breast Surgery (ABS), British Association 
of Plastic and Reconstructive and Aesthetic Surgeons 
(BAPRAS), and Mammary Fold Research Network. 
PARTICIPANTS 
Inclusion criteria
All female patients over the age of 16 years electing to 
undergo breast conserving wide local excision or excision 
biopsy, where localisation is required, will be eligible for 
inclusion in the initial study. 
Exclusion criteria
Women will be excluded from the study if there is a 
contraindication to the localisation device. For instance, 
for Magseed® this includes:
i) They have had an iron oxide injection within the 
previous six months
ii) They have a pacemaker or implantable electronic 
device in situ
iii) They are unable or do not provide consent for 
Magseed® localisation
iv) They are not suitable for general anaesthetic 
v) They have allergies prohibiting the use of Magseed® 
localisation
Registration
Sites wishing to join the study must complete a registration 
process. This involves registration of site demographics and 
identification of a Principal Investigator for each site. The 
registration process is electronic and will generate a copy 
of all the necessary study documentation for the Principal 
Investigator, including the study protocol and patient 
information documents. Once the study site has local audit 
approval, access to the electronic database is granted.
Recruitment
Potential participants will be identified by the local breast 
team through breast and oncoplastic clinics, multi-
disciplinary team meetings and consultant surgeon or 
specialist breast research nurse review.
Women will be given a patient information leaflet 
explaining the Magseed® procedure when this is 
performed. Participants will be informed of the 
innovative nature of the device and that outcome data 
for Magseed® are limited until the results are known. 
An identical process of consent will be followed as new 
devices are bolted onto the platform study. 
Procedural learning and standardisation
Breast centres undertaking a new localisation technique 
should complete a quality assurance period prior to 
participation to ensure adequate expertise in radiological 
placement and surgical removal. Surgeons competent in 
breast localisation excision will be eligible to participate, 
but the study requires a minimum standard of surgical 
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competence in performing the procedure with each 
device to ensure consistent quality in localisation and 
excision for analysis. It is anticipated that new devices 
(Magseed®) may require initial training prior to study 
participation to allow familiarisation with the new device. 
This may include a trainee with less experience, provided 
a suitably experienced consultant lead is identified to 
supervise. The operating surgeon must have completed 
a minimum of 10 wire-guided wide local excisions within 
the previous 12 months, and/or a minimum of five 
Magseed® localisation surgeries, prior to participation in 
the initial platform study arm. 
Scheduling of wire-guided localisation should be 
performed as per local Trust standard practice. There is a 
recommended technical procedure for use of the Magseed® 
to ensure consistent quality in insertion, localisation, and 
surgical excision (Appendix 1). As patients are recruited 
and individuals gain expertise in surgical technique, it is 
planned that technical guidance will be iteratively updated, 
and the results distributed to participating breast centres 
via a monthly electronic newsletter.
OUTCOMES
CLINICAL OUTCOMES
The primary outcome is to evaluate the identification 
rate of the index lesion in the pathological specimen, 
comparing the comparator of wire localisation versus the 
intervention of the new localisation technique.
Secondary clinical objectives which will be assessed 
include margin status, accuracy of placement, 
pathological weight of specimen, reoperation rate, 
cancellations on day of surgery, duration of surgery, 
complications (e.g. haematoma, infection, wound 
dehiscence, 30-day readmission, 30-day reoperation, 
deep vein thrombosis). Patient and tumour data 
including age, imaging reports, preoperative and 
postoperative pathology will also be studied. Outcomes 
for any subsequent arms may be modified to reflect both 
internal and external scientific discoveries after the initial 
analysis, once the Magseed® study arm is complete.
DATA COLLECTION AND MANAGEMENT
No patient identifiable data will be reported for the 
purpose of this cohort study. Patients will be allocated 
a unique alphanumeric study identification number 
and all data will be anonymised. Clinical data for each 
patient will be collected via an online case report form 
hosted on REDCap (Research Electronic Data Capture). 
REDCap is a secure, web-based database designed for 
use in collaborative clinical research [21] and hosted by 
the University of Oxford. Access is limited to study 
executives via a password protected account and all 
web-based information is encrypted. 
Online case report forms used to capture data on 
REDCap will be divided into eight domains (identifiers, 
preoperative radiology, preoperative oncology, 
localisation data, pathology, perioperative complications, 
30-day complication data, shared learning events). 
Shared learning inputs will comprise of a ‘yes/no’ 




Power calculations estimate 950 patients per group 
sufficient to establish equivalence between Magseed® 
and wire-guided localisation for the initial study arm, 
based on an upper limit of observed one-sided 95% 
confidence interval for a difference between failure rates 
expected to be less than 0.9%, with 80% power. 
STATISTICAL ANALYSIS
All data analysis will be conducted centrally using 
standard statistical software (e.g. SPSS) and will be led by 
the University of Manchester. Simple descriptive summary 
statistics will be calculated to describe the main parameters 
and variations in practices of breast localisation technique. 
Categorical data will be summarised by counts and 
percentages, and continuous data by the mean or median 
and their associated measures of dispersion, dependent 
on the distribution of the data [22]. Regression analysis 
will be used to control for predictive variables. Differences 
between groups using unpaired t-tests, Mann-Whitney U 
tests and Chi squared tests, as appropriate. Any qualitative 
data, which comprises free text responses to open ended 
items from the online case report forms, will be presented 
according to overall themes using a thematic or content 
analysis as appropriate [23]. 
INTERIM ANALYSIS
Interim analyses will be undertaken when a total of 
400 patients from a minimum of 10 centres have been 
recruited to the study. Centres with an overall index 
lesion identification rate audited as an outlier (>3SD 
from control) will be contacted to check the validity of 
the results, explore potential reasoning behind this (e.g. 
learning curve and training requirement) and escalated 
as per local hospital trust protocol if persistently 
anomalous (>3 SD). 
PATIENT AND PUBLIC INVOLVEMENT
Oversight of the study will be led by the iBRA-net 
audit Steering Committee which has representation 
from surgeons, trainees, patient representatives, and 
academics with experience of study management and 
statistics. This group meets twice a year, with additional 
executive meetings arranged as required via e-mail or 
teleconferencing. Regular monthly auditing to review 
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study progress, protocol compliance and dissemination 
of technical recommendations will be overseen by the 
study executive committee.
The overall results from the study will be discussed 
with the iBRA-net Study Group collaborative to inform the 
planning and design of the next phase of the platform 
trial, provided the evidence shows that Magseed® meets 
the required safety standards [24] and as new surgical 
devices emerge. 
SHARED LEARNING
Central incident reporting is encouraged for unanticipated 
learning events or issues with new surgical devices [25]. 
Shared learning will be achieved in two phases using a 
novel mixed-method approach to explore the feasibility 
of each technique by asking participating surgeons to 
complete online +/- face-to-face shared learning. 
ONLINE SHARED LEARNING
Prospective shared learning documentation will be 
collected for each patient using the online case report 
form on REDCap for the duration of the study. Surgeons 
will be prompted to identify problems related to device 
insertion (e.g. insertion of the localisation device >2cm 
from the index lesion), perioperative issues before the 
induction of anaesthesia (e.g. percutaneous failure 
to localise lesion) or intraoperative events (e.g. failure 
to remove index lesion). A free-text box will be used in 
which clinicians may expand on the nature of the shared 
learning event and to document any technical tips 
applied to overcome them. 
The iBRA-net localisation steering committee will 
regularly review shared learning events and feedback 
to study participants to allow iterative improvement of 
surgical technique [26]. 
FOCUS GROUP INTERVIEWS
A purposive sample of participating breast surgeons and 
radiologists will be invited to participate in a focus group 
interview to further discuss any shared learning points 
raised in the online database and to refine any technical 
modifications outlined in participating UK breast centres. 
Interviews will be conducted using a semi-structured 
topic guide based on the online shared learning 
outcomes, including the complications identified, 
rationale and clinical outcome. Data will be analysed 
via thematic analysis and participating surgeons will be 
invited to review the final outcomes to ensure a valid 
reflection of learning events is reported.
EVALUATION OF SHARED LEARNING
Shared learning from the online database will be 
summarised thematically. Major technical modifications 
or learning events identified will disseminated in a timely 
fashion via a monthly electronic newsletter update 
to participating surgeons during the study, to enable 
iterative sharing of technical tips, potential pitfalls and to 
accelerate the learning curve.
Overall evaluation of the online database and focus 
group shared learning will be undertaken at the end of 
the first localisation device (Magseed®) study arm to 
inform the subsequent arms of the platform study. A 
thematic analysis will be conducted independently by >3 
co-authors of both the written and interview qualitative 
data to identify common learning events, triangulate key 
findings identified from each method and to ascertain 
how each shared learning approach may have impacted 
upon surgical practice. 
Additional qualitative feedback may be sought 
from all participants via an electronic questionnaire to 
determine the number of surgeons who used shared 
learning to inform their clinical practice, and to aid an 
evaluation of the value of each of the shared learning 
methodologies applied, to iteratively inform the next 
phase of the study.
DISSEMINATION OF RESULTS 
The platform study results will be propagated through 
national and international presentation and publication 
in peer reviewed journals. All presentations and 
publications will be made on behalf of the UK Surgical 
Trainee Research Collaborative and iBRA-net Study Group 
collaborative. Study centres will be presented with a 
summary of the study data in the form of a webinar and 
access to the published manuscript.
The results of this study can be used for future consent 
of patients receiving localisation devices, ensuring their 
consent is informed of the likely outcomes associated 
with the device in multi-centre practice.
Results from the shared learning analysis will be used 
to inform the subsequent arms of the platform study 
and may be transferable to other surgical trials of new 
devices or techniques.
APPENDIX 1
i) Magseed® user summary
•	 Magseed® is licenced to be placed up to 30 days in 
advance of operation date.
•	 Magseed® should not be placed until all 
investigations have been completed, e.g. post 
neoadjuvant chemotherapy magnetic resonance 
imaging.
•	 Patients should receive an information leaflet about 
Magseed® prior to insertion.
•	 Prospective outcomes of Magseed® localisation 
should be audited.
31Bromley et al. International Journal of Surgery: Protocols DOI: 10.29337/ijsp.136
•	 Absolute exclusion criteria for using Magseed®:
○  Patients with a Pacemaker or implanted device in 
the chest wall
○  Patients requiring an MRI scan between 
Magseed® placement and surgery
○  Patients who have received Sienna (iron oxide) 
injection in the previous six months
•	 Caution criteria for using Magseed®:
○ Metal coronary stents. 
○  Failure to locate Magseed® in anaesthetic room 
prior to anaesthetic induction
○  Failure to locate and differentiate between 
Magseed® clips if multiple seeds are used for 
bracketing lesions that are close together. 
•	 Ensure Sentimag® device is switched on in theatre at 
least 20 minutes prior to first use to allow sufficient 
time to warm up and identify faults.
•	 Wire localisation can continue to be available when 
clinicians feel that this would be preferable for an 
individual patient.
ii) Magseed® user technical guidelines 
1. Connect the probe with the base unit ensuring that 
the arrows on the probe connectors are at the top of 
the connectors 
2. Switch on the Sentimag at least 15–20 minutes 
prior to use. The dial needs to be set at position 2 
throughout the procedure. 
3. Cover the probe with a sterile single-use sheath 
4. Balance the Sentimag using the balance button or 
the footswitch Probe.
5. The operator should always hold the probe behind the 
black ring. Make sure all metal including rings, retractors, 
lights, name badges are out of the range of the probe.
6. To perform a balance of the base unit, the operator 
should either press the button marked on the base 
unit or press the footswitch. After five seconds the 
scales symbol will stop and the Sentimag should 
display a value close to zero. Scales will require 
balancing when the stationary balance symbol is 
displayed (e.g. after start-up), when the sensitivity 
setting of the Sentimag is changed, before starting 
use after a minimum of 15 minutes warm-up, before 
taking any measurements on the patient. 
7. For transcutaneous measurement, sweep the probe 
and apply some pressure around the breast until the 
Magseed® is located (to get a signal from Magseed® 
the probe must be within 3cm). Pivot the probe 
around the hotspot to maximize the signal and 
pinpoint the lesion.
8. Confirm the tracing of the Magseed®. Palpation of 
the skin should result in a rise and fall in the signal = 
a characteristic change in Sentimag value and audio 
frequency. The signal will increase when the probe is 
pointing directly at a Magseed® lesion and decrease 
when angled away.
9. Pin-point technique. Remove probe from incision, 
balance in air and recheck suspect lesion. 
10. Balance in-vivo: From within the incision, withdraw 
2–3 cm from the suspect lesion and re-balance. 
A clear positive signal should be seen when you 
examine the Magseed® lesion again.
For more information please visit: https://www.endomag.
com/Magseed /overview/.
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